Continuous intravenous arabinosyl cytosine infusions delivered by a new portable infusion system

Joseph Bottino; Kenneth B. McCredie; D. W.H. Ho; Emil J. Freireich; Richard Buckles; Susan Herbst; Millie Lawson

doi:10.1002/1097-0142(197906)43:6<2197::AID-CNCR2820430606>3.0.CO;2-1

Continuous intravenous arabinosyl cytosine infusions delivered by a new portable infusion system

Joseph Bottino, Kenneth B. McCredie, D. W.H. Ho, Emil J. Freireich, Richard Buckles, Susan Herbst, Millie Lawson

Leukemia

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Eighty‐six adult patients with acute leukemia were given 116 continuous intravenous arabinosyl cytosine (Ara‐C) infusions (for 24 to 432 hours) with a new portable infusion device. The infusor is powered by interchangeable elastomeric 25 ml balloon reservoirs loaded from standard syringes. The reservoir contents are discharged at nearly constant pressure through an adjustable resistance element, thereby providing flow rates from 0.4 to 2.0 ml/hour. Serum levels of labeled Ara‐C delivered by the infusor were found to achieve steady‐state therapeutic levels within 24 hours. The average‐flow‐rate‐to‐indicator‐setting ratio determined for each infusion via scalp vein needles was 0.9 ± 0.2. Delivery through catheters was more reliable and an average‐flow‐rate‐to‐indicator‐setting ratio of 0.1 ± 0.1 was observed. The therapeutic effectiveness of Ara‐C in combination with other agents was not compromised by this delivery system. Eleven of 14 patients who received all their induction Ara‐C through the infusor achieved complete remission.

Original language	English (US)
Pages (from-to)	2197-2201
Number of pages	5
Journal	Cancer
Volume	43
Issue number	6
DOIs	https://doi.org/10.1002/1097-0142(197906)43:6<2197::AID-CNCR2820430606>3.0.CO;2-1
State	Published - Jun 1979

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/1097-0142(197906)43:6<2197::AID-CNCR2820430606>3.0.CO;2-1

Cite this

@article{7c9b7f96c91540aba71d2ee2dd25caae,

title = "Continuous intravenous arabinosyl cytosine infusions delivered by a new portable infusion system",

abstract = "Eighty‐six adult patients with acute leukemia were given 116 continuous intravenous arabinosyl cytosine (Ara‐C) infusions (for 24 to 432 hours) with a new portable infusion device. The infusor is powered by interchangeable elastomeric 25 ml balloon reservoirs loaded from standard syringes. The reservoir contents are discharged at nearly constant pressure through an adjustable resistance element, thereby providing flow rates from 0.4 to 2.0 ml/hour. Serum levels of labeled Ara‐C delivered by the infusor were found to achieve steady‐state therapeutic levels within 24 hours. The average‐flow‐rate‐to‐indicator‐setting ratio determined for each infusion via scalp vein needles was 0.9 ± 0.2. Delivery through catheters was more reliable and an average‐flow‐rate‐to‐indicator‐setting ratio of 0.1 ± 0.1 was observed. The therapeutic effectiveness of Ara‐C in combination with other agents was not compromised by this delivery system. Eleven of 14 patients who received all their induction Ara‐C through the infusor achieved complete remission.",

author = "Joseph Bottino and McCredie, {Kenneth B.} and Ho, {D. W.H.} and Freireich, {Emil J.} and Richard Buckles and Susan Herbst and Millie Lawson",

year = "1979",

month = jun,

doi = "10.1002/1097-0142(197906)43:6<2197::AID-CNCR2820430606>3.0.CO;2-1",

language = "English (US)",

volume = "43",

pages = "2197--2201",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "6",

}

TY - JOUR

T1 - Continuous intravenous arabinosyl cytosine infusions delivered by a new portable infusion system

AU - Bottino, Joseph

AU - McCredie, Kenneth B.

AU - Ho, D. W.H.

AU - Freireich, Emil J.

AU - Buckles, Richard

AU - Herbst, Susan

AU - Lawson, Millie

PY - 1979/6

Y1 - 1979/6

N2 - Eighty‐six adult patients with acute leukemia were given 116 continuous intravenous arabinosyl cytosine (Ara‐C) infusions (for 24 to 432 hours) with a new portable infusion device. The infusor is powered by interchangeable elastomeric 25 ml balloon reservoirs loaded from standard syringes. The reservoir contents are discharged at nearly constant pressure through an adjustable resistance element, thereby providing flow rates from 0.4 to 2.0 ml/hour. Serum levels of labeled Ara‐C delivered by the infusor were found to achieve steady‐state therapeutic levels within 24 hours. The average‐flow‐rate‐to‐indicator‐setting ratio determined for each infusion via scalp vein needles was 0.9 ± 0.2. Delivery through catheters was more reliable and an average‐flow‐rate‐to‐indicator‐setting ratio of 0.1 ± 0.1 was observed. The therapeutic effectiveness of Ara‐C in combination with other agents was not compromised by this delivery system. Eleven of 14 patients who received all their induction Ara‐C through the infusor achieved complete remission.

AB - Eighty‐six adult patients with acute leukemia were given 116 continuous intravenous arabinosyl cytosine (Ara‐C) infusions (for 24 to 432 hours) with a new portable infusion device. The infusor is powered by interchangeable elastomeric 25 ml balloon reservoirs loaded from standard syringes. The reservoir contents are discharged at nearly constant pressure through an adjustable resistance element, thereby providing flow rates from 0.4 to 2.0 ml/hour. Serum levels of labeled Ara‐C delivered by the infusor were found to achieve steady‐state therapeutic levels within 24 hours. The average‐flow‐rate‐to‐indicator‐setting ratio determined for each infusion via scalp vein needles was 0.9 ± 0.2. Delivery through catheters was more reliable and an average‐flow‐rate‐to‐indicator‐setting ratio of 0.1 ± 0.1 was observed. The therapeutic effectiveness of Ara‐C in combination with other agents was not compromised by this delivery system. Eleven of 14 patients who received all their induction Ara‐C through the infusor achieved complete remission.

UR - http://www.scopus.com/inward/record.url?scp=0018645697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018645697&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(197906)43:6<2197::AID-CNCR2820430606>3.0.CO;2-1

DO - 10.1002/1097-0142(197906)43:6<2197::AID-CNCR2820430606>3.0.CO;2-1

M3 - Article

C2 - 455216

AN - SCOPUS:0018645697

SN - 0008-543X

VL - 43

SP - 2197

EP - 2201

JO - Cancer

JF - Cancer

IS - 6

ER -

Continuous intravenous arabinosyl cytosine infusions delivered by a new portable infusion system

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this